CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice

Cancer Immunology, Immunotherapy

Volumn 54, Issue 10, 2005, Pages 944-952

  Sabel, Michael S ^a   Hess, Stephen D ^b   Egilmez, Nejat K ^b   Conway Jr , Thomas F ^c   Chen, Fang An ^d   Bankert, Richard B ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Human CTLA 4; Lymphocytes; SCID Mice; Xenografts

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10A8; MONOCLONAL ANTIBODY P2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LEUKOCYTE; LUNG TUMOR; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; HUMANS; IMMUNOCONJUGATES; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 23944490393     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0668-3     Document Type: Article

References (35)

1. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
2. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287
3. Cohen PA, Peng L, Plautz GE, et al. (2000) CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Critical Reviews in Immunology 20:17-56
4. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181-273
5. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839
6. Perez-Diaz A, Spiess PJ, Restifo NP, et al. (2002) Intensity of the vaccine-elicited immune response determines tumor clearance. J Immunol 168:338-347
7. Chambers CA, Allison JP (1997) Co-stimulation in T cell responses. Curr Opin Immunol 9:396-404
8. Mueller DL, Jenkins MK, Schwartz RH (1989) Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445-480
9. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Immunol 2:116-126
10. Brunet JF, Denizot F, Luciani MF, et al (1987) A new member of the immunoglobulin superfamily- CTLA-4. Nature 328:267-270
11. Linsley PS, Brady W, Urnes M, et al. (1991) CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 174:561-569
12. Linsley PS, Greene JL, Brady W, et al (1994) Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801
13. van der Merwe PA, Bodian DL, Daenke S, et al. (1997) CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 185:393-403
14. Walunas TL, Lenschow DJ, Bakker CY, et al. (1994) CLTA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
15. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. J Exp Med 182:459-465
16. Waterhouse P, Penninger JM, Timms E, et al. (1995) CTLA-4 deficiency causes lymphoproliferative disorder with early lethality. Science 1995; 270:985-988
17. Tivol EA, Borriello F, Schweitzer AN, et al. (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role for CLTA-4. Immunity 3:541-547
18. Egen JG, Kuhns MS, Allison JP. (2002) CLTA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3:611-618
19. Lee KH, Holdorf AD, Dustin ML, et al. (2002) T cell receptor signaling precedes immunological synapse formation. Science 295:1539-1542
20. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736
21. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366
22. Bankert RB, Egilmez NK, Hess SD (2001) Human/SCID chimeric models for preclinical evaluation of anti-cancer therapies: Applications, limitations and future directions. Trends Immunol 22:368-393
23. Egilmez NK, Hess SD, Chen FA, et al. (2002) CD4+ effector T-cells mediate an indirect IL-12 and IFN-gamma-dependent suppression of autologous lung tumor xenografts in SCID mice. Cancer Res 62:2611-2617
24. Iwanuma Y, Chen FA, Egilmez NK, et al (1997) Antitumor immune response of human peripheral blood lymphocytes co-engrafted with tumor nito severe immunodeficient mice. Cancer Research 57:2937-2942
25. Linsley PS, Greene JL, Tan P, et al. (1992) Co-expression and functional cooperation of CTLA-4 and CD28 on activated T-lymphocytes. J Exp Med 176:1595-1604
26. Bender A, Sapp M, Schuler G, et al. (1996) Improved methods for the generation of dendritic cells from non-proliferating progenitors in human blood. J Immunol Methods 196:121-135
27. Mosmann T (1993) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
28. Liu Y (1997) Is CTLA-4 a negative regulator for T-cell activation? Immunol Today 18:569-72
29. Thompson CB, Allison JP (1997) The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445-450
30. Yang Y (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte associated molecule-4 blockade: The effect is manfiested only at the restricted tumor-bearing stages. Cancer Res 57:4036-4041
31. Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CLTA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA (10067-10071)
32. Hurwitz AA, Foster BA, Kwon ED, et al (2000) Combination immunotherapy of primary prostate cancer ina transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444-2448
33. Mokyr MB, Kalinchenko T, Gorelik L, Bluestone JA (1998) Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Research 58:5301-5304
34. Phan GQ, Yang JC, Sherry RM, et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377
35. Hodi FS, Mihm MC, Soiffer RJ, et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717